Giacomin A.,University of Padua |
Sergio A.,University of Padua |
Vanin V.,University of Padua |
Gazzola A.,University of Padua |
And 2 more authors.
Digestive Diseases | Year: 2012
Therapeutic options in advanced stage hepatocellular carcinoma have been very poor until the discovery of new therapeutic agents that target the molecular pathways involved in hepatocarcinogenesis. In this paper we try to review the most important molecular agents in development, with a specific focus on sorafenib's role and safety profile, especially in the treatment of patients with suboptimal liver function. Copyright © 2012 S. Karger AG, Basel.